Related Experiment Videos
Poly I:C/poly-L-lysine: potent inducer of interferons in primates
Summary
Polyriboinosinic:polyribocytidylic acid (poly I:C) complexed with poly-L-lysine effectively induces high levels of interferon in monkeys. This complex shows potential for sustained interferon production without long-term hyporesponsiveness.
Area of Science:
- Immunology
- Virology
- Biochemistry
Background:
- Polyriboinosinic:polyribocytidylic acid (poly I:C) is known to induce interferon.
- The development of stable and effective interferon inducers is crucial for antiviral therapies.
- Previous formulations of poly I:C have limitations in solubility and efficacy.
Purpose of the Study:
- To develop a soluble and potent interferon-inducing complex using poly I:C and poly-L-lysine.
- To evaluate the efficacy of this complex in inducing circulating interferon in non-human primates.
- To assess the durability of the interferon response and potential for hyporesponsiveness.
Main Methods:
- Preparation of a soluble poly I:C/poly-L-lysine complex with a specific lysine to nucleotide molar ratio (0.5).
- Testing complexes with varying poly-L-lysine molecular weights for interferon induction capacity in grivet monkeys.
- Administering the optimal complex repeatedly to grivet monkeys to assess sustained response and hyporesponsiveness.
Main Results:
- A soluble complex was formed at a lysine to nucleotide ratio of 0.5, stable up to 2.0 mg/ml.
- Poly-L-lysines with molecular weights of 10(4) daltons or greater significantly enhanced interferon induction (10- to 100-fold).
- The poly I:C/poly-L-lysine complex effectively induced high interferon titers in grivet monkeys, rhesus monkeys, chimpanzees, and marmosets, with sustained levels upon repeated administration and no long-term hyporesponsiveness.
Conclusions:
- The soluble poly I:C/poly-L-lysine complex is a potent inducer of circulating interferon in various primate species.
- Optimized complex formulation allows for sustained interferon production without inducing long-term hyporesponsiveness.
- This complex represents a promising candidate for therapeutic applications requiring interferon induction.